[Weight gain in patients with schizophrenia and schizoaffective disorder induced by the long-term treatment with atypical antipsychotics].
To specify the effect of different atypical antipsychotics on weight gain, 346 patients with schizophrenia and schizoaffective disorder have been examined. The influence of risperidone (88 patients), olanzapine (84 patients), clozapine (61 patients), quetiapine (68 patients) and amisulpiride (45 patients) used as a monotherapy has been studied during 1,5 years. Frequency of weight gain for every drug and peculiarities of the dynamics of pharmacogenic weight gain and body mass index in some stages (after 3, 6, 12 and 18 months) have been revealed. The data obtained allow to conclude that the long-term therapy with olanzapine, clozapine and risperidone exert a more marked influence on the body mass as compared to quetiapine and amisulpiride regardless of the patient's sex.
Gorobets
L N
LN
D000293:Adolescent; D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D015992:Body Mass Index; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000139:chemically induced* / Q000453:epidemiology; D011618:Psychotic Disorders / Q000188:drug therapy*; D012559:Schizophrenia / Q000188:drug therapy*; D013997:Time Factors; D015430:Weight Gain / Q000187:drug effects*
D014150:Antipsychotic Agents